S100A8/S100A9 through PAD4 activation of neutrophil extracellular traps promotes granulomatous lobular mastitis

Tingting Zhu, Hao Yu, Wei Wang, Yulu Sun, Shengjia Wang, Dongwen Ma, Yongzhong YaoFrontiers in Immunology 2025 · DOI

TL;DR

Granulomatous lobular mastitis (GLM), a chronic inflammatory breast condition, is driven by neutrophil extracellular traps (NETs). This study reveals that the S100A8/S100A9 protein complex is a key upstream activator of NET formation via PAD4, and targeting this pathway with paquinimod effectively reduces inflammation in GLM, suggesting a novel therapeutic strategy.

What Problem Does This Paper Address?

Granulomatous lobular mastitis (GLM) is a relatively rare, benign inflammatory condition of the breast with an unclear cause and pathogenesis. While it's known to involve granulomas and immune cell infiltration, the specific mechanisms driving its chronic inflammation are not well understood. Recent research has implicated neutrophil extracellular traps (NETs) – web-like structures released by activated neutrophils – in various inflammatory and autoimmune diseases. However, their precise role and the regulatory pathways involved in GLM have remained elusive. This paper aims to elucidate the role of NETs in GLM pathogenesis and identify potential therapeutic targets by investigating the involvement of the S100A8/S100A9 protein complex and its interaction with PAD4.

Methods

The study employed a multi-pronged approach:

  • Human Tissue Analysis: Western blot, immunohistochemistry (IHC), and immunofluorescence (IF) were used to detect and quantify NET markers (citrullinated histone H3 [CitH3] and myeloperoxidase [MPO]) and the S100A8/S100A9 protein complex in breast tissue samples from GLM patients and healthy controls (HCs). IF was crucial for visualizing the colocalization of NET components.
  • In Vitro Neutrophil Assays: Human neutrophils were isolated from healthy donors. A NETosis model was established using phorbol 12-myristate 13-acetate (PMA). The study then used specific inhibitors, paquinimod (S100A8/S100A9 inhibitor) and Cl-amidine (PAD4 inhibitor), to assess their impact on NET formation, measured by extracellular DNA release (dsDNA assay) and protein expression (Western blot).
  • Co-immunoprecipitation (Co-IP): This technique was used to investigate the direct interaction between S100A8/S100A9 and PAD4 in activated neutrophils.
  • Animal Model of GLM: A mouse model of GLM was established to evaluate the therapeutic efficacy of paquinimod and Cl-amidine in vivo. This involved assessing mammary gland inflammation (histology, diameter measurements) and NET marker expression after treatment.

Datasets

The study utilized two primary sources of data:

  • Human Samples: Surgical specimens from 40 patients diagnosed with GLM and 20 healthy women (control group) were collected. Peripheral blood from 20 healthy control subjects was used for neutrophil isolation.
  • Animal Model: Female BALB/c mice were used to establish the GLM model.

No new benchmark datasets were introduced.

Key Insights and Ideas

  • NETs are Central to GLM: The elevated presence of NET markers (CitH3 and MPO) in GLM tissues strongly suggests that NET formation is a significant contributor to the pathology of this condition.
  • S100A8/S100A9 as a Key Upstream Activator: The study identified S100A8/S100A9 as not just a marker but a potent upstream trigger of NETosis, acting independently of DNA entrapment. This protein complex appears to initiate a positive feedback loop that perpetuates inflammation.
  • S100A8/S100A9-PAD4 Axis: A critical mechanistic insight is the direct, activation-dependent interaction between S100A8/S100A9 and PAD4. This interaction is crucial for promoting NET formation, highlighting a specific molecular pathway.
  • Diagnostic Potential: The combined expression of S100A8/S100A9, MPO, and CitH3 showed significant predictive value for GLM, suggesting their utility as diagnostic biomarkers.
  • Therapeutic Promise of Inhibitors: Both paquinimod (S100A8/S100A9 inhibitor) and Cl-amidine (PAD4 inhibitor) demonstrated significant efficacy in reducing NET formation in vitro and alleviating GLM pathology in vivo, pointing towards promising therapeutic avenues.

Key Results

  • Elevated NET Markers in GLM: Western blot and IHC showed significantly higher levels of CitH3 and MPO in GLM tissues compared to HCs.
  • Increased S100A8/S100A9 Expression: S100A8/S100A9 expression was also significantly elevated in GLM patients. ROC curve analysis indicated that S100A8/S100A9, MPO, and CitH3 were all significant predictors of GLM.
  • Inhibition of NETs by Paquinimod and Cl-amidine: In vitro, both paquinimod (at 100 µM) and Cl-amidine (at 200 µM) significantly inhibited dsDNA release (NET formation) induced by PMA. Western blot confirmed that paquinimod reduced S100A8/S100A9, CitH3, and PAD4, while Cl-amidine reduced PAD4 and CitH3.
  • S100A8/S100A9 Induces NETosis: Exogenous S100A8/S100A9 alone induced NET formation comparable to PMA.
  • S100A8/S100A9-PAD4 Interaction: Co-IP experiments confirmed an activation-dependent interaction between S100A8/S100A9 and PAD4, which persisted even after DNA degradation, indicating a direct or stable complex interaction.
  • Therapeutic Efficacy in Mouse Model: In the GLM mouse model, treatment with paquinimod and Cl-amidine significantly reduced mammary gland inflammation, diameter, and NET accumulation, as evidenced by reduced MPO and CitH3 levels and decreased NET colocalization.

Limitations and Future Work

The authors acknowledge several limitations:

  • Interspecies Differences: The study's findings in mouse models may not perfectly translate to human pathology due to differences in neutrophil biology, particularly the stronger reliance of murine neutrophils on PAD4 for NET formation.
  • In Vitro Model Limitations: The use of PMA as a potent, non-physiological NETosis inducer in in vitro experiments does not fully replicate the complex inflammatory microenvironment of GLM. Future studies could explore more disease-relevant stimuli like Corynebacterium species or cytokines.
  • Mechanism of Paquinimod: While the interaction between S100A8/S100A9 and PAD4 was confirmed, the precise mechanism by which paquinimod acts and the functional significance of this interaction require further elucidation. It's unclear if paquinimod acts solely via the S100A8/S100A9-PAD4 complex or also through broader proinflammatory signaling pathways (e.g., TLR4, RAGE).
  • Potential for Increased Infection Susceptibility: Chronic inhibition of S100A8/S100A9, which plays a role in antimicrobial defense, could potentially increase susceptibility to infections. Future therapeutic strategies might consider localized drug delivery to minimize systemic exposure.
  • Sample Size: While the study provided valuable insights, expanding the sample size in future research could enhance the representativeness and reliability of the findings.

Future work should focus on clarifying the precise molecular mechanisms of the S100A8/S100A9-PAD4 interaction, exploring alternative disease-relevant stimuli for NETosis, investigating the role of TLR4 and RAGE in GLM, and conducting clinical trials to evaluate the safety and efficacy of paquinimod for GLM and other inflammatory diseases.

Summary updated

Abstract

The present findings indicated that NETs contribute to the pathogenesis of GLM. S100A8/S100A9 plays a critical role in promoting NET formation via PAD4 activation. Targeting this axis with paquinimod effectively inhibits NETosis and alleviates GLM, suggesting a promising therapeutic strategy for GLM and other inflammatory diseases.
BibTeX
@inproceedings{zhu2025s,
  author = {Tingting Zhu and Hao Yu and Wei Wang and Yulu Sun and Shengjia Wang and Dongwen Ma and Yongzhong Yao},
  title = {{S100A8/S100A9 through PAD4 activation of neutrophil extracellular traps promotes granulomatous lobular mastitis}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1672538},
}
Figure